PACS Group, Inc. (PACS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $45.63, PACS Group, Inc. (PACS) is priced for +10.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/PACS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.8pp.

Reconcile: at the x-ray's 9.3% required return this reads ~5.4 years; the models below use their own rates.

How unusual the bet is: within-range

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.4%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• PACS is a fast-growing skilled-nursing operator, and the right way to read it is as a roll-up still in expansion mode, not a mature business. At $36.62 only the growth method reaches the price; the static frames all say richly valued, which is the signature of a compounding bet.
• The numbers have recovered after a scare. Q1 2026 revenue rose 11.2% to $1.42 billion, occupancy improved to 90.9%, and net income jumped, but the company also restated 2024 results, removing as much as $65 million of prior revenue tied to a Medicare-waiver review.
• The single biggest lever is government reimbursement. Skilled nursing lives on Medicare and Medicaid rates, so policy is the external variable with the most control over the thesis, and the price does not obviously discount that exposure.

Bull Case

Frame PACS correctly first: this is a growth-stage skilled-nursing roll-up, not a mature healthcare facility owner, and that changes how the numbers should be read. The company acquires under-occupied nursing facilities, raises their occupancy and skilled-patient mix, and compounds the cash flow. The recent results show the model working. Q1 2026 revenue grew 11.2% to $1.42 billion, same-store skilled-nursing revenue rose 8.0%, and occupancy improved to 90.9% from 89.6%, with skilled mix up in both revenue and nursing patient days (PACS Q1 2026, stocktitan). The filings describe management monitoring skilled mix as the core operating metric because the payor mix significantly affects revenue and profitability (FY2025 10-K, accession 0002001184-26-000005). Rising occupancy and a richer skilled mix are precisely the levers that turn an acquired facility into a profit center.

The demographic tailwind is the structural case. The US population over 80 is growing rapidly, and skilled-nursing capacity has not kept pace, so an operator that can run facilities efficiently and acquire more has a long runway of demand. PACS competes in the same model as Ensign, the cohort benchmark, whose own filing describes attracting higher-acuity patients to lift revenue (ENSG FY2025 10-K, accession 0001125376-26-000007). PACS has been growing its share count at about 8% a year to fund acquisitions, which is dilutive but is the standard fuel for a roll-up in expansion phase. Interest coverage is comfortable at about 13.7x and net debt of roughly $276 million is modest against trailing operating income near $381 million.

The valuation reflects a company priced for that compounding. At $36.62 only the forward-growth method reaches the price (DCF Exit Multiple at $77), while the asset and earnings-power methods sit below it, the classic shape of a durability premium for a business the static frames cannot fully value. The implied assumption is about 8.1% annual operating growth for five years, which is well within what a successful skilled-nursing roll-up can deliver given the demographic demand and the occupancy-and-mix lever. If PACS keeps lifting occupancy toward the low 90s and continues acquiring facilities, the growth method is the right lens and the price is defensible.

Bear Case

Lead with the external variable that has the most leverage over PACS, because for a skilled-nursing operator it dwarfs everything else: government reimbursement. The overwhelming majority of revenue comes from Medicare and Medicaid, whose rates are set by federal and state policy, not by the market. A change to skilled-nursing reimbursement rates, the introduction of staffing mandates, or tighter eligibility rules can compress margins across the entire portfolio at once, with no offsetting lever available to the company. The current price implies steady operating growth, but it does not obviously price the tail risk that a single regulatory decision resets the economics of the business. For a company this dependent on a single payor structure, that policy exposure is the dominant risk and the hardest to hedge.

The governance and accounting history is the second red flag, and it is recent. PACS restated its consolidated financial statements for the first two quarters of 2024, removing as much as $65 million of previously reported skilled-nursing revenue after an internal review, following an activist firm's allegations about potential misuse of a Medicare waiver during the pandemic (McKnight's Long-Term Care News). A restatement of that size, tied to how the company recognized government revenue, is exactly the kind of issue that should make an investor cautious about the quality and durability of the reported numbers. The improved Q1 2026 results are encouraging, but they come from a company that was recently found to have misstated revenue, and rebuilding that trust takes more than one clean quarter.

The roll-up structure compounds both risks. Growth by acquisition requires continuous capital and integration, the share count is climbing about 8% a year to fund it, and each deal must clear a higher bar as the base grows. A skilled-nursing roll-up is leveraged to occupancy, labor availability and cost, and reimbursement all at once, and the asset and earnings-power methods say the price is already rich on the current numbers (Simple Excess Return $16, Graham Number $15, against the $36.62 price (June 27, 2026)). The reverse-DCF floored at the current price, meaning the inversion could not find much positive growth implied. The bear case is a recently-restated, acquisition-dependent operator whose fortunes rest on government reimbursement it cannot control, priced for continued compounding with little cushion if policy turns or the next quarter disappoints.

Valuation

PACS should be valued as a growth-stage roll-up, and the methods reflect that posture. That dispersion is the signature of a durability premium: the static frames, which assume no further compounding, cannot reach a price that is paying for the roll-up to keep executing. Several methods are distorted and should be ignored, the Earnings Power Value figure prints near zero on a low normalized-EBIT input, and the ROIC-justified figure reflects an artificially low trailing return on capital from heavy acquisition activity.

The inversion gives the cleaner read. At $36.62 the market pays about 27x company-wide operating income, implying roughly 8.1% annual operating growth for five years, computed at a 7% cost of capital with 4% terminal growth, where each point of cost of capital moves the implied growth about 9 points. That 8.1% pace is within what a successful skilled-nursing operator can deliver through occupancy gains, skilled-mix improvement, and acquisitions, so the priced-in assumption reads as within range. There is a measurement caveat: the trailing operating-income figures from different sources diverge by more than 10% here, so the precise multiple should be held loosely.

Catalysts

PACS Group reported Q1 2026 results with revenue up 11.2% to $1.42 billion, same-store skilled-nursing revenue up 8.0%, occupancy improved to 90.9% from 89.6%, and net income up sharply, while raising its 2026 EBITDA outlook (PACS Q1 2026, stocktitan). The company also restated its consolidated financial statements for the first two quarters of 2024, removing as much as $65 million of previously reported revenue following an internal review tied to a pandemic-era Medicare waiver, after an activist firm raised concerns in late 2024 (McKnight's Long-Term Care News).

The forward setup is a recovery story against a regulatory backdrop. The catalysts to watch are the continued return to timely, clean financial reporting and any further developments from the audit-committee review, since restored trust in the numbers is the gate to the stock being valued on fundamentals. Operationally, watch occupancy trends (toward and above 91%), skilled-mix improvement, and the pace of facility acquisitions that drive the roll-up. The dominant external catalyst is government reimbursement policy: Medicare and Medicaid rate decisions, any federal staffing mandates, and state Medicaid budgets all have direct leverage over margins. The next quarterly print is a test of whether the operating momentum holds and whether the accounting overhang is genuinely behind the company.

Peer Cohorts (Per Segment, With Filing Citations)

Post-acute / skilled nursing healthcare services (reported)

• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: , reviews segment income for each operating segment to evaluate performance and allocate capital resources. For more information about our operating segments, as well as financial information, see Part II., Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and Note 7,…
• FY2025 10-K: …cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below: • Shift of Patient Care to Lower Cost Alternatives - The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than…
• NHC (NATIONAL HEALTHCARE CORP)
• FY2025 10-K: …competitive with other market rates. ● Medical Specialty Units. All our skilled nursing facilities participate in the Medicare program, and we have expanded our range of offerings by the creation of facility-specific medical specialty units such as our memory care units and sub-acute nursing units. Our trained staff…
• FY2025 10-K: …non-operating income from equity in earnings of unconsolidated investments, dividends and realized gains and losses on marketable securities, interest income, and other miscellaneous non-operating income. 4 Quality of Patient Care The Centers for Medicare and Medicaid Services ("CMS") introduced the Five-Star Quality…
• SEM (SELECT MEDICAL HOLDINGS CORP)
• FY2025 10-K: …that refer patients to our rehabilitation hospitals. We provide our facilities within our rehabilitation hospital segment with centralized accounting, treasury, payroll, legal, operational support, human resources, compliance, management information systems, health information, credentialing, physician contracting…
• FY2025 10-K: …employees, aids us in our marketing efforts to referral sources, and helps us negotiate payor contracts. In our critical illness recovery hospital segment, we operated 104 critical illness recovery hospitals in 28 states as of December 31, 2025. In our rehabilitation hospital segment, we operated 38 rehabilitation…
• BTSG (BrightSpring Health Services, Inc.)
• FY2025 10-K: …with each other and with home health and hospice. Aligning to Value-Based Care Reimbursement Models with Innovative Solutions The scale and depth of our complementary platform of diverse yet related customer and patient services - that complex patients require - positions us at the forefront with governmental and…
• FY2025 10-K: …supported for patients outside of retail pharmacies. The Company's footprint of pharmacies covers all 50 states with a localized model that features "white-glove" and customized programs and allows for faster response times and a better customer and patient experience. We service customer locations typically multiple…
• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping and transportation services. Many consumers need such services on a long-term basis to address chronic or acute conditions. Our personal care segment also includes staffing services, with clients including assisted…
• FY2025 10-K: …assistance with activities of daily living, primarily to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company provides physical, emotional and spiritual care for people who are terminally ill as well as…
• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …to patients including private duty nursing and therapy services, (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be…
• FY2025 10-K: …can help our patients recover after a hospitalization or surgery and assist patients in managing chronic illnesses. We also help our patients manage their medications. Through our care, we help our patients recover more fully in the comfort of their own homes, while remaining as independent as possible. HH Services…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.